8-K: Gritstone Bio Announces Promising Interim Phase 2 Data for Personalized Cancer Vaccine in Colorectal Cancer

Gritstone Bio's personalized cancer vaccine, GRANITE, shows a potential benefit in progression-free survival for patients with metastatic colorectal cancer, particularly those with low disease burden.

Summary

• Gritstone Bio announced interim results from its Phase 2 study of the GRANITE vaccine in combination with immune checkpoint blockade for metastatic microsatellite stable colorectal cancer (MSS-CRC).
• The study randomized 104 patients, with 69 included in the treated analysis (39 in the GRANITE arm and 30 in the control arm).
• The interim data, cut as of August 19, 2024, showed a 21% relative risk reduction of progression or death with GRANITE compared to the standard of care in the treated population.
• A more significant 38% relative risk reduction was observed in patients with low circulating tumor DNA (ctDNA) levels at baseline.
• 13 out of 39 patients in the GRANITE arm and 7 out of 30 in the control arm remained on the study and free of progression.
• The GRANITE vaccine demonstrated a favorable safety profile, with no patients discontinuing treatment due to adverse events.
• The company plans to discuss the progression-free survival (PFS) data with the FDA to determine the next steps, potentially including a Phase 2 or 3 trial using ctDNA levels as eligibility criteria.

Sentiment

Score: 8

Explanation: The document presents positive interim results for the GRANITE vaccine, with a clear benefit in progression-free survival, particularly in a subgroup of patients. The safety profile is also favorable. The company's plan to discuss the data with the FDA and potentially move to a Phase 3 trial is also positive. However, the study was not statistically powered for PFS and there were some patients who did not advance to treatment.

Positives

• The GRANITE vaccine demonstrated a statistically significant reduction in the risk of disease progression or death, particularly in patients with low ctDNA levels.
• The vaccine showed a favorable safety profile with no treatment discontinuations due to adverse events.
• The presence of functional neoantigen-specific T cells in all tested patients suggests a strong immune response.
• The study identified low baseline ctDNA as a potential prognostic and predictive factor.

Negatives

• 35 patients did not advance to study treatment after oxaliplatin, with 15 withdrawing consent, 8 due to disease progression, and 12 for other reasons.
• One treatment-related serious adverse event (fatigue) occurred in the GRANITE arm, although the patient continued treatment after recovery.
• The study was not statistically powered for progression-free survival (PFS).

Risks

• The study was not statistically powered for PFS, so the results should be interpreted with caution.
• The study had a significant number of patients who did not advance to treatment after oxaliplatin, which could impact the generalizability of the results.
• The clinical benefit was most notable in patients with low disease burden, which may limit the applicability of the vaccine to all patients with MSS-CRC.
• The next steps for the GRANITE vaccine are dependent on discussions with the FDA.

Future Outlook

The company plans to review the PFS data with the FDA and agree on next steps to advance GRANITE, including a potential Phase 2 or 3 trial using ctDNA levels as eligibility criteria.

Management Comments

• The company plans to review the PFS data with the U.S. Food and Drug Administration in the coming months and agree on next steps to advance GRANITE.

Industry Context

The development of personalized cancer vaccines is a growing area of interest in the oncology field, with several companies exploring similar approaches. This announcement positions Gritstone Bio as a key player in this space, particularly in the treatment of MSS-CRC, which has limited treatment options.

Comparison to Industry Standards

• The 21% relative risk reduction in progression or death observed in the overall treated population is a promising result compared to standard of care treatments for MSS-CRC.
• The 38% relative risk reduction in patients with low ctDNA levels is particularly notable, suggesting a potential for personalized treatment approaches.
• Other companies such as Moderna and BioNTech are also developing personalized cancer vaccines, but the specific approach and target population of Gritstone's GRANITE vaccine differ, making direct comparisons challenging.
• The use of ctDNA levels as a predictive biomarker is gaining traction in oncology, and Gritstone's approach aligns with this trend.

Stakeholder Impact

• Shareholders may react positively to the promising interim data.
• Patients with MSS-CRC may benefit from the development of this new treatment option.
• Employees of Gritstone Bio may be motivated by the positive results.

Next Steps

• The company plans to review the PFS data with the U.S. Food and Drug Administration.
• The company will agree on next steps to advance GRANITE, including a potential Phase 2 or 3 trial using ctDNA levels as eligibility criteria.

Key Dates

Keywords

GRANITE, cancer vaccine, colorectal cancer, MSS-CRC, immunotherapy, progression-free survival, ctDNA, clinical trial, FDA, neoantigen